<DOC>
	<DOCNO>NCT01635686</DOCNO>
	<brief_summary>The purpose study compare safety pharmacokinetic characteristic DWP422 25 mg ENBREL 25MG PFS INJ . subcutaneous injection healthy male volunteer .</brief_summary>
	<brief_title>Comparison Safety Pharmacokinetic Characteristics DWP422 25 mg With Those ENBREL 25MG PFS INJ . After Subcutaneous Injection Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>1 . Healthy male , 20 45 year age moment screen 2 . Body mass index 19.0 27.0 kg/m2 1 . Hypersensitivity response experimental comparator drug 2 . The tuberculosis patient latent tuberculosis patient</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>